<SEC-DOCUMENT>0001558370-22-017549.txt : 20221114
<SEC-HEADER>0001558370-22-017549.hdr.sgml : 20221114
<ACCEPTANCE-DATETIME>20221114070321
ACCESSION NUMBER:		0001558370-22-017549
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20221109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221114
DATE AS OF CHANGE:		20221114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		221380090

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plx-20221109x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/13/2022 9:30:34 PM -->
      <!-- iXBRL Library version: 1.0.8263.24741 -->
      <!-- iXBRL Service Job ID: 6f3b1f1a-b3da-4042-8e96-0b84e9898625 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:plx="http://protalix.com/20221109" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:EntityCentralIndexKey" id="Tc_T7mz-mJC3kOA4LC7sa89mg_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:AmendmentFlag" id="Tc_sVUa17hMq0W33_jgPd3y5w_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="plx-20221109.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-09</xbrli:startDate><xbrli:endDate>2022-11-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_239c7b11_f40d_47ec_916b_9096b38d7ece"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:DocumentType" id="Narr_QS8DILQKSk-3YvWrdMdGHA"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of Earliest Event Reported): </b><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_nAleQOddbE-f-k4qBCE5zA"><b style="font-weight:bold;">November&#160;9, 2022</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:EntityRegistrantName" id="Narr_xWEMR8EXtkSkzahOuJHSlA"><b style="font-weight:bold;">Protalix BioTherapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db44e2d3_a4d8_4690_a9da_b28605fc200d"></a><a id="Tc_JQ7_Ttzh7UqTUY8P70Iw6g_2_0"></a><a id="Tc_DeEmh_b2SES2VNx1WbSV4w_2_2"></a><a id="Tc_4pTybFpYE0eeLoC6JJBdTw_2_4"></a><a id="Tc_8iP-OknIqkyxD1_0DjjYWg_6_0"></a><a id="Tc_KKVcss88FUWLW2ZPWOT18g_7_0"></a><a id="Tc_ueV8O83Ke0S7kJlbLXi21Q_7_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_QXIDQcOE2UezTFAT11XFxQ_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:EntityFileNumber" id="Tc_eZA7gIe0KUOloKqa95GvwQ_1_2"><b style="font-weight:bold;">001-33357</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:EntityTaxIdentificationNumber" id="Tc_LvImTlvUi0y95kNnu0jVaQ_1_4"><b style="font-weight:bold;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:EntityAddressAddressLine1" id="Tc_Dl4hfLEUy0qcDk-GpQIdKw_4_0"><b style="font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:EntityAddressAddressLine2" id="Tc_9eJfTcXG5USFrM5aGX44Wg_5_0"><b style="font-weight:bold;">Suite 100</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:EntityAddressCityOrTown" id="Narr_v76KKfgy_06MsMf6PXjmsg"><b style="font-weight:bold;">Hackensack</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:EntityAddressStateOrProvince" id="Narr_O1B3d_Mly063zKsTR3G8vQ"><b style="font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:EntityAddressPostalZipCode" id="Tc_4BCiZXZ-eUGThdqmUYBkJQ_6_4"><b style="font-weight:bold;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">&#160;<b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code </b><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:CityAreaCode" id="Narr_-ju0D57mLEyp1hgWnHOeSA"><b style="font-weight:bold;">201</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:LocalPhoneNumber" id="Narr_GgrIjYgJKUuBx-FdNXuhOg"><b style="font-weight:bold;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report.)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:10pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_lchaQwHWk0CStm6eLRZ_tg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_QN8_TqgYAEKiZPuLHLMNeA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_tvjnCsTJ_0KHZOAcMj336A"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_UCN9vhWtIEOzzlABS30FDA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77e804a_d223_4729_927d_c6bf13fbe4e3"></a><a id="Tc_MBTSe1ADwE6S3vSdKqC92Q_1_0"></a><a id="Tc_huSYJ-kL70S0Jwilv9kZWQ_1_1"></a><a id="Tc_EkQWARFG6EuZwaWRxdXXgw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:Security12bTitle" id="Tc_PBSWgn6wgk6c6f7kVAKYfg_2_0">Common stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" name="dei:TradingSymbol" id="Tc_U56AqH8BG0qxXjtTQNy94A_2_1">PLX</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_zqJe2aFa90C_qZQzl8QZfg_2_2">NYSE American</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_zo1V11_yfkmqSeIktAMmXA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:Times New Roman;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;2.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Results of Operations and Financial Condition</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On November&#160;14, 2022, Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter ended September&#160;30, 2022 and provided a business update on recent corporate and regulatory developments. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;8.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Events</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">On November&#160;14, 2022, the Company, together with its commercialization partner, Chiesi Global Rare Diseases, a business unit of the Chiesi Group, today announced the resubmission on November&#160;9, 2022 of a Biologics License Application (BLA) to the U.S.&#160;Food and Drug Administration (FDA) for PRX-102 (pegunigalsidase alfa) for the treatment of adult patients with Fabry disease. Pegunigalsidase alfa is a purposefully-designed, long-acting recombinant, PEGylated, cross-linked &#945;-galactosidase-A investigational product candidate. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:normal;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:86.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit No.</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Description</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20221109xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release dated November&#160;14, 2022 (Earnings Release)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.2</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20221109xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release dated November&#160;14, 2022</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;14, 2022</p></td><td colspan="3" style="vertical-align:top;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:40.02%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>plx-20221109xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/13/2022 09:30:31 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:6.05%;padding-right:6.05%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><img src="plx-20221109xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:39pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:128.4pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Company to host conference call and webcast today at 8:30 a.m. EST</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">C</b><b style="font-weight:bold;">ARMIEL, Israel, November&#160;14, 2022</b> -- Protalix BioTherapeutics, Inc. (NYSE&#160;American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx<sup style="font-size:9pt;vertical-align:top;">&#174;</sup> plant cell-based protein expression system, today reported financial results for the third quarter ended September&#160;30, 2022 and provided a business update on recent corporate and regulatory developments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">&#8220;We are happy we have reached a significant milestone for our company with the recent BLA resubmission to the FDA,&#8221; said Dror Bashan, Protalix&#8217;s President and Chief Executive Officer. &#8220;We believe PRX-102, if approved, has the potential to significantly impact patients living with this rare, life-threatening genetic disease. As we approach potential approval and commercialization of PRX-102, we affirm our dedication to our mission of bringing new medicines to patients with serious diseases. We are grateful to our team members and external partners for their continued commitment to this program.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2022 Third Quarter and Recent Business Highlights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Regulatory Updates</i></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">On November</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">&#160;</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9, 2022, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), resubmitted a biologics license application (BLA) to the U.S.&#160;Food and Drug Administration (FDA) for PRX-102 (pegunigalsidase alfa) for the treatment of adult patients with Fabry disease. </font><font style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">The BLA re-submission included the final two year analyses of our phase III </font><i style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:normal;">BALANCE</i><font style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"> clinical trial, which analyses were completed in July 2022, and long-term data from our open-label extension study of PRX-102 in adult patients treated with a 2 mg/kg every four weeks dosage of PRX 102. The initial BLA included a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase I/II clinical trial of PRX 102, including the related extension study, interim clinical data from our phase III </font><i style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:normal;">BRIDGE</i><font style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"> clinical trial and safety data from our on-going clinical studies of PRX 102 in adult patients receiving 1 mg/kg every two weeks</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Third Quarter 2022 Financial Highlights </b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">The Company recorded revenues from selling goods of $8.8&#160;million during the three months ended September&#160;30, 2022, an increase of $4.3&#160;million, or 96%, compared to revenues of $4.5&#160;million for the three months ended September 30,&#160;2021. An increase of $3.4&#160;million in sales to Pfizer Inc., resulting from timing differences, and an increase of $2.4&#160;million in sales to Chiesi was partially offset by a decrease of $1.5&#160;million in sales to Brazil resulting from timing differences.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Revenue from licenses and R&amp;D services for the three months ended September&#160;30, 2022 were $5.4&#160;million, a decrease of $2.1&#160;million, or 28%, compared to revenues of $7.5&#160;million for the three months ended September&#160;30, 2021. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Cost of goods sold was $7.1&#160;million for the three months ended September&#160;30, 2022, an increase of $3.4 million, or 91%, from cost of goods sold of $3.7&#160;million for the three months ended September&#160;30, 2021. The increase in cost of goods sold was primarily the result of the increase in sales of goods.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:6.05%;margin-right:6.05%;margin-top:30pt;page-break-after:always;width:87.91%;border-width:0;"><div style="max-width:100%;padding-left:6.05%;padding-right:6.05%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">For the three months ended September&#160;30, 2022, our total research and development expenses were approximately $7.4&#160;million comprised of approximately $4.9&#160;million in subcontractor-related expenses, approximately $1.7&#160;million of salary and related expenses, approximately $0.2 million of materials-related expenses and approximately $0.6 million of other expenses. For the three months ended September&#160;30, 2021, our total research and development expenses were approximately $7.3&#160;million comprised of approximately $4.8&#160;million in subcontractor-related expenses, approximately $1.6&#160;million of salary and related expenses, approximately $0.1 million of materials-related expenses and approximately $0.8&#160;million of other expenses. Total increase in research and developments expenses was $0.1 million, or 1%, for the three months ended September&#160;30, 2022 compared to the three months ended September&#160;30, 2021.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Selling, general and administrative expenses were $2.8&#160;million for the three months ended September&#160;30, 2022, a decrease of $0.2&#160;million, or 7%, compared to $3.0&#160;million for the three months ended September&#160;30, 2021. The decrease was primarily due to a decrease in salary related and selling costs.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Financial expenses, net were $0.4&#160;million for the three months ended September&#160;30, 2022, compared to $2.3&#160;million for the three months ended September&#160;30, 2021. The decrease resulted primarily from lower interest and debt amortization costs due to a decrease in our outstanding notes from an aggregate principal amount of $57.92 million of 2021&#160;Notes to an aggregate principal amount of $28.75 million of 2024&#160;Notes, and an increase in the exchange rate of New Israeli Shekels for U.S. Dollars over the period.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Cash, cash equivalents and short-term bank deposits were approximately $20.8&#160;million at September&#160;30, 2022.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Net loss for the three months ended September&#160;30, 2022 was approximately $3.6&#160;million, or $0.07 per share, basic and diluted, compared to a net loss of approximately $4.2&#160;million, or $0.09 per share, basic and diluted, for the same period in 2021.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Conference Call and Webcast Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The Company will host a conference call today, November&#160;14, 2022, at 8:30 a.m. Eastern Standard Time, to review the corporate and regulatory developments, which will also be available by webcast. To participate in the conference call, please dial the following numbers prior to the start of the call:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Conference Call Details:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Monday, November 14, 2022, 8:30&#160;a.m. Eastern Standard Time (EST)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:90pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Domestic:  </font></font>1-877-423-9813</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">International: <font style="display:inline-block;width:22.36pt;"></font>1-201-689-8573</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><font style="white-space:pre-wrap;">Conference ID:  </font><font style="display:inline-block;width:9.7pt;"></font>13734038</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Webcast Details:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The conference will be webcast live from the Company&#8217;s website and will be available via the following links:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 0pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:90pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">Company Link:</font></font><font style="letter-spacing:-0.15pt;">https://protalixbiotherapeutics.gcs-web.com/events0</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 0pt 18pt;"><font style="letter-spacing:-0.15pt;white-space:pre-wrap;">Webcast Link:  </font><font style="display:inline-block;width:15.94pt;"></font><font style="font-size:11pt;">https://tinyurl.com/2s6sdx5e</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-indent:0pt;width:90pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Conference ID:</font></font>13734038</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:12pt;background:#ffffff;margin:0pt;">Please access the websites at least 15 minutes ahead of the conference to register, download and install any necessary audio software.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The conference call will be available for replay for two weeks on the Events Calendar of the Investors section of the Company&#8217;s website, at the above link.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:6.05%;margin-right:6.05%;margin-top:30pt;page-break-after:always;width:87.91%;border-width:0;"><div style="max-width:100%;padding-left:6.05%;padding-right:6.05%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="color:#373737;font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="color:#000000;font-weight:bold;">About Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S.&#160;Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human &#945;-Galactosidase-A protein for the treatment of Fabry disease; alidornase alfa or PRX-110, for the treatment of various human respiratory diseases or conditions; PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX-119, a plant cell-expressed long action DNase&#160;I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;">To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and &#8220;intend,&#8221; and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: the risk that the FDA will find that the resubmitted BLA for PRX-102 is incomplete or not properly reviewable at the time of submission and, accordingly, refuse to file the resubmitted BLA or request additional information; risks related to the acceptance by the FDA of the resubmitted BLA for PRX-102, and the timing, progress and likelihood of final approval by the FDA and European Medicines Agency (EMA) of the resubmitted BLA and of a Marketing Authorization Application, respectively, for PRX-102 and, if approved, whether the use of PRX-102 will be commercially successful; likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen; risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; failure or delay in the commencement or completion of our preclinical studies and clinical trials for our other product candidates, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and inability to monitor patients adequately during or after treatment; the risk that the FDA, EMA, or other foreign regulatory authorities may not accept or approve a marketing application we file for any of our other product candidates, and other risks relating to the review process; risks associated with the novel coronavirus disease, or COVID-19, outbreak and variants, which may adversely impact our business, preclinical studies and clinical trials; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; the risk that the results of the clinical trials of our product candidates will not support the applicable claims of safety or efficacy, or that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain and manage our relationship with our collaborators, distributors or partners; risks related to the </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:6.05%;margin-right:6.05%;margin-top:30pt;page-break-after:always;width:87.91%;border-width:0;"><div style="max-width:100%;padding-left:6.05%;padding-right:6.05%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;">amount and sufficiency of our cash and cash equivalents and short-term bank deposits; risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish; risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector; our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services; delays in our preparation and filing of applications for regulatory approval; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; risks related to our expectations with respect to the potential commercial value of our product and product candidates; and other factors described in our filings with the U.S.&#160;Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Investor Contact</b><br>Chuck Padala, Managing Director<br>LifeSci Advisors<br>646-627-8390<br>chuck@lifesciadvisors.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">###</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-family:'&amp;quot';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:6.05%;margin-right:6.05%;margin-top:30pt;page-break-after:always;width:87.91%;border-width:0;"><div style="max-width:100%;padding-left:6.05%;padding-right:6.05%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;"><a name="CONSOLIDATEDBALANCESHEETS_216383"></a>CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 10,720</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 38,985</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 10,091</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 8,651</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 3,442</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,736</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,285</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 14,562</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 17,954</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 45,760</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 61,666</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 18pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,418</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 2,077</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,677</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,962</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,854</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,960</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 56,709</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 73,665</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES NET OF CAPITAL DEFICIENCY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 5,639</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 6,986</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 12,870</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 16,433</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,000</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,207</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 14,793</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 8,550</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 34,302</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 33,176</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 28,111</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 27,887</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 11,790</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,779</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 2,472</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,031</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,376</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 33,921</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 46,525</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 68,223</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 79,701</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 18pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CAPITAL DEFICIENCY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (11,514)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (6,036)</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Total liabilities net of capital deficiency</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 56,709</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 73,665</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:6.05%;margin-right:6.05%;margin-top:30pt;page-break-after:always;width:87.91%;border-width:0;"><div style="max-width:100%;padding-left:6.05%;padding-right:6.05%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;"><a name="CONSOLIDATEDSTATEMENTSOFOPERATIONS_58886"></a>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share and per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:10pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.7093468%;padding-left:0pt;padding-right:0pt;width:103.41%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 21,222</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 12,260</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 8,812</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,506</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 17,799</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 17,541</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 5,371</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 7,548</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 39,021</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 29,801</font></p></td><td style="vertical-align:middle;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 14,183</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 12,054</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD (1)</b></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (17,195)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (13,201)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (7,074)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (3,703)</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES (2)</b></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (23,732)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (22,093)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (7,386)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (7,282)</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (3)</b></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (8,613)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (9,263)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,848)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,954)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING LOSS</b></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (10,519)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (14,756)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (3,125)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,885)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,879)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (6,613)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (639)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,410)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,211</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 403</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 197</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 96</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES, NET</b></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (668)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (6,210)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (442)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,314)</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OTHER INCOME</b></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 51</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (11,187)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (20,915)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (3,567)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (4,199)</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS PER SHARE OF COMMON STOCK &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.24)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.48)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.07)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.09)</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING LOSS PER SHARE &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 47,582,733</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 43,761,769</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 49,498,105</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 45,556,647</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 24pt;"><b style="font-weight:bold;">(1) Includes share-based compensation</b></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 24pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 58</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 217</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 36</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 65</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 24pt;"><b style="font-weight:bold;">(2) Includes share-based compensation</b></p></td><td style="vertical-align:bottom;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 24pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 275</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 524</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 114</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 154</font></p></td></tr><tr><td style="vertical-align:bottom;width:46.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 24pt;"><b style="font-weight:bold;">(3) Includes share-based compensation</b></p></td><td style="vertical-align:bottom;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 24pt;"><font style="font-size:8pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,213</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,216</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 272</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 344</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:6.05%;margin-right:6.05%;margin-top:30pt;page-break-after:avoid;width:87.91%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>plx-20221109xex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/13/2022 09:30:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Exhibit 99.2</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.16%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><img src="plx-20221109xex99d2001.jpg" alt="Graphic" style="display:inline-block;height:39pt;width:128.25pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><img src="plx-20221109xex99d2002.jpg" alt="GRD Logo" style="display:inline-block;height:48.75pt;width:128.25pt;"></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:12pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;">Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S.&#160;Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">CARMIEL, Israel</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> and </font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">BOSTON</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, November&#160;14, 2022 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx</font><sup style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> plant cell based protein expression system, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced the resubmission on November&#160;9, 2022 of a </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Biologics License Application (BLA) to the U.S.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Food and Drug Administration (FDA) for PRX-102 (pegunigalsidase alfa) for the treatment of adult patients with Fabry disease. </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Pegunigalsidase alfa is a purposefully-designed, long-acting recombinant, PEGylated, cross-linked &#945;-galactosidase-A investigational product candidate.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;">The BLA resubmission includes </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">a comprehensive set of clinical and manufacturing</font><font style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;"> data. The data were compiled from studies that involved more than 140 Fabry disease patients with up to five years of follow up including all three </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">completed studies in the PRX-102 Phase&#160;III clinical program including the BALANCE study, the BRIDGE study and the BRIGHT study, as well as the phase&#160;I/II clinical trial of PRX-102.</font><font style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;"> The </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">phase&#160;I/II data</font><font style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;"> includes data compiled from </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">the related extension study succeeding the phase&#160;I/II study.</font><font style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;"> The BLA resubmission also includes safety data compiled from the ongoing phase&#160;III extension studies of PRX-102. If</font><font style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;"> approved, </font><font style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix</font><font style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">will be eligible to receive a milestone payment from Chiesi upon BLA approval.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:12pt;margin:0pt;"><font style="color:#242424;font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix and Chiesi anticipate that the FDA will complete its review of the resubmission within six months of receipt.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;The resubmission of the BLA represents a significant milestone for Protalix and we believe it has meaningful potential for patients and families affected by Fabry disease. Fabry disease is a serious, life-threatening, rare genetic disorder, the ultimate consequences of which range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system,&#8221; said Dror Bashan, Protalix&#8217;s President and Chief Executive Officer. &#8220;Together with Chiesi, we are committed to continuing to work with the FDA toward our goal of achieving regulatory approval and making PRX-102 available to patients with this rare disease in the United States.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The European Medicines Agency (EMA) is currently reviewing the marketing authorization application for PRX-102, and interactions with the EMA are ongoing.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;Many people who are living with Fabry disease still have existing unmet needs including access to treatment and the burden of regular infusions, and we believe it is important to deliver a potential new treatment option,&#8221; said Giacomo Chiesi, head of Chiesi Global Rare Diseases. &#8220;Together with Protalix, we thank the investigators and study participants who have made reaching this milestone possible and have supported our joint commitment to bringing this new treatment option to the Fabry patient community.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">About Fabry Disease</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Fabry disease is an X-linked inherited disease that results from deficient activity of the lysosomal &#945;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">-</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">Galactosidase-A enzyme resulting in progressive accumulation of abnormal deposits of a fatty substance called </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">globotriaosylceramide (Gb</font><sub style="font-family:'Times New Roman','Times','serif';font-size:9pt;letter-spacing:-0.15pt;vertical-align:sub;">3</sub><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">) in blood vessel walls throughout a person&#8217;s body. Fabry disease occurs in one person per 40,000 to 60,000. Fabry patients inherit a deficiency of the &#945;-Galactosidase-A enzyme, which is normally responsible for the breakdown of Gb</font><sub style="font-family:'Times New Roman','Times','serif';font-size:9pt;letter-spacing:-0.15pt;vertical-align:sub;">3</sub><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;">. The abnormal storage of Gb</font><sub style="font-family:'Times New Roman','Times','serif';font-size:9pt;letter-spacing:-0.15pt;vertical-align:sub;">3</sub><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;"> increases with time and, accordingly, Gb</font><sub style="font-family:'Times New Roman','Times','serif';font-size:9pt;letter-spacing:-0.15pt;vertical-align:sub;">3</sub><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;"> accumulates, primarily in the blood and in the blood vessel walls. The ultimate consequences of Gb</font><sub style="font-family:'Times New Roman','Times','serif';font-size:9pt;letter-spacing:-0.15pt;vertical-align:sub;">3</sub><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.15pt;"> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure &#8211; particularly of the kidneys, but also of the heart and the cerebrovascular system.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:12pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">About PRX-102</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">PRX-102 (pegunigalsidase alfa) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant &#945;-Galactosidase-A enzyme. It is a novel, PEGylated enzyme replacement therapy (ERT) under development for the treatment of Fabry disease. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties, resulting in a molecule with unique pharmacokinetic parameters. In clinical studies, PRX-102 has been observed to have a circulatory half-life of approximately 80 hours. The Company designed PRX-102 to potentially address the continued unmet clinical need in Fabry patients.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">About Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human &#945; Galactosidase A protein for the treatment of Fabry disease; alidornase alfa or PRX-110, for the treatment of various human respiratory diseases or conditions; PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">About Chiesi Global Rare Diseases</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit www.chiesirarediseases.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About Chiesi Group</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;">Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years&#8217; experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">achieve its mission of improving people&#8217;s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialty care and consumer-facing self-care). The Group&#8217;s Research and Development center is based in Parma and works alongside 6 other important research and development hubs in France, the U.S., Canada, China, the UK, and Sweden to pursue its pre-clinical, clinical, and regulatory programs. In 2018 Chiesi has changed its legal status to a Benefit Corporation, according to the law in Italy, USA and, more recently, in France, by incorporating common benefit objectives into its bylaws, to generate value for its business, for the society and the environment. Since 2019, Chiesi has been the world&#8217;s largest B Corp certified pharmaceutical group. B Corps are global leaders convinced to leverage business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to report annually in a transparent way about its progress in achieving the common benefits objectives it has set forward. The Group is committed to becoming carbon neutral by the end of 2035.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">For more information, please visit </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">www.chiesi.com</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and &#8220;intend,&#8221; and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: risks related to the timing, progress and likelihood of final approval by the FDA and European Medicines Agency (EMA) of the resubmitted Biologics License Application (BLA) and of a Marketing Authorization Application, respectively, for PRX-102 and, if approved, whether the use of PRX-102 will be commercially successful; likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and inability to monitor patients adequately during or after treatment; delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process; risks associated with the novel coronavirus disease, or COVID-19, outbreak, which may adversely impact our business, preclinical studies and clinical trials; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; the risk that the results of the clinical trials of our product candidates will not support the applicable claims of safety or efficacy, or that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain and manage our relationship with our collaborators, distributors or partners; risks related to the amount and sufficiency of our cash, cash equivalents and short-term deposits; risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services; delays in our preparation and filing of applications for regulatory approval; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">and/or technologies by other companies and institutions; potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; and other factors described in our filings with the U.S. Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="color:#373737;font-weight:bold;">Investor Contact</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="color:#373737;">Chuck Padala</font><font style="color:#373737;">, Managing Director</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="color:#373737;">LifeSci Advisors</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="color:#373737;">646-627-8390</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:12pt;background:#ffffff;margin:0pt;"><font style="color:#0000ff;">chuck@lifesciadvisors.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="color:#373737;font-weight:bold;">Source: Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;background:#ffffff;margin:0pt;"><font style="color:#373737;">###</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>plx-20221109xex99d2001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20221109xex99d2001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T *L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WGX 7?Q^^
M/OP^'BFT^+]KHT7VN:T^S3:!;S-F,@%MP ZYZ8KH_%_Q#^.?[,PMO$/CG4=)
M^)/@+SDAU&ZT^R%G>V 9L"3:N%(R0.<Y) .W(-8_[!_Q=\$>!_@.--\0^+-&
MT74/[6NY?LM]>QQ2;&*[6VL0<'UK3_:I_:+\*_$3X?WWPR^'U[%XX\7^)REC
M#;:3^^CMT+J6D=P-HP!Z\=3@"@#I?VJOBGXKTB/X3P?#[Q,FB#Q?JR67]H?9
M8[A&BE1?+?:ZG@;PW&":DE^%/[1]FADM?C9H]W,HRL5WX<B6-CZ$J"0/< UQ
M?[1/AE_!*?LN^'Y91-)I7B"QLGD'1FC2)21[9%?7-[KFG:;%+)=ZA:VL<0)D
M>>94"8ZY)/% 'AWP+^/7B75_'FJ_#+XFZ3:Z-X^TZW%W#/8L?LFIVW'[V('H
M1D$CZ\ J0+7Q]_:%O_ NOZ3X$\"Z./%/Q*UI=]KI[-B"SBYS/.01A>"0,C@$
MD@8SYUH/B2S^.W[<>F>(?"+?;_#?@G19K._UJ#F"XGE\P+$C]& \S(QUV,1Q
M@F]^R5;Q^,?C5\<?'FH#SM6&O-HELTG+6]M%G"#T!"Q_]\4 :=C^S7\4O%L
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M?Q;^)-AK2C9+X8FU>;^UDN/^> MA'O9\\# *GKG'- 'L?CG]HO1/"GPO\/\
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M+6[^(/@+_A&_#=S-' VM:=JJ:A%8L[!4^U*$1D0L0#(NY02,X'-=-\1?BO\
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M,#% ';A%!S@9]<4AB4G)Y-%% "3V\=S$T4J++&PPR. P/U!IT<:Q(J(H1%&
MJC  HHH  @!) Y/6@(%! XS110 *@4\<5&;2$W G,2>>!M$NT;@/3/6BB@"1
MD#')YHV\#KQ110!%%9P0&0Q0QQ&0Y<H@&X^_K7D7CQ0O[37PF Z#2M<_]!M:
M** /7H+."V+F&)(BYR_EJ%W'U..M2LH=2K %2,$'O110!';VT5I&(X(DAC'.
MR-0H_(47%K%=QF.:-)8SU210P/X&BB@!ZQJF-H P,# Z#TH$:KNP.&ZBBB@
M"!5P.![5%%900-(T4,<32'+E%"EC[XZT44 /EMXY]OF1K)M.1N4'!]>:>!@4
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>plx-20221109xex99d2002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20221109xex99d2002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !B 0$# 2(  A$! Q$!_\0
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MX'T+PW*07B/$MYT=L]]GW![[NO%?:G[(?QS3XX?">SN[J4-K^F;;+45+99G
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MFUU32+^VU/3;I!)!=V<JRQ2J>ZLI((^E9'Q%^)/ACX2^$[WQ-XOUFVT+0[,
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M'?%@U/2VTJXDS<V@S'NZM'_]8\?0BO1LTTW%W1O1K5*%2-6E)QDM4UNF?/\
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M%F$;)J6N6R2K+&949?-#,&7^($ @_6OZ6K2%;>VBB4 *BA0 ,  #% $U%%%
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MXD SN<*2HQWYQ3]8T33O$-B]EJEA;:E9N06M[N%98V(.02K C@@&KM 'QO\
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MJ7_/NW_?0_QHKZ7_ +*MO^>2?]\T4[!8N4444QA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5E>)W:/1+DHQ
M4X'(..]%% 'A'A(#5O%7^G#[9N8Y^T?/GYAZU]#V\,<$:QQ(L<:@!408 'L*
+**2$B6BBBF,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>plx-20221109xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20221109xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T *L# 2(  A$! Q$!_\0
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M@F]^R5;Q^,?C5\<?'FH#SM6&O-HELTG+6]M%G"#T!"Q_]\4 :=C^S7\4O%L
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M?Q;^)-AK2C9+X8FU>;^UDN/^> MA'O9\\# *GKG'- 'L?CG]HO1/"GPO\/\
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M+6[^(/@+_A&_#=S-' VM:=JJ:A%8L[!4^U*$1D0L0#(NY02,X'-=-\1?BO\
M\(=JNE:!HVBW/BKQ;JJ/-::/:2I$%A0@//-*WRQ1 LHW'))("@FO-?C'\:/"
MOQ8^'.K^!O FH6_C3Q+XGM'TVWL],!F2V64;6N+AP,0QQ@ECN()(  )-8/Q;
M\'Q^"/BMH7B;Q!KWB;1O",_AZ'0[C7O#]R\1LKB&1F0W)56(AD#GY\85E^;&
M0: /4M"^,>LV/BS3/#GCWPF?"-YJ[M%I=_;7ZWUC=S*I8P&0*C1R[02%9<-M
M.TDC%=-X5^(2>)_'/C3PVMD]N_AJ:UA>X:0,MQY\"S @8RNW=CG.:^?;'2O!
M_P 0/'_A;2?#/B[QI\2X['4(M4O+M]>:33-+\D[XY))/+*R2%P%6)3N(+$E0
M.>Q@\;:1\&OC[\09/&5XN@:7XI33[[2M5O 4M)C#;^3-"9?NK(I56VL1D,".
ME 'H=_\ $ZY7X@^(?!^FZ&VH:IIFAPZS"6NEB2Z:226-8<D'8<Q?>.1\W3BO
M*?V;/$WBV]UOXBVVH>#_ +'IL_BG49KV^_M>.4V<_E1?Z.$"Y<=/G&!\W3BK
M/PF\=6/Q'_:D\:ZSI$<\FB?\(Q86UGJ$D+)'>A;FX+21;@-R;F*ANAVDC(P:
MZ3]G]"J_%W*D9\;ZD1D8R/*@YH ROAM\5/#OP]_9R\!7NGZ;J]V-3B6ST70O
M-6ZU"\F9G*Q;\*I("LS.=JJH)/2M6\^-OB[P8+;4/'?P[DT+PW-*D4NJZ5JB
M:D; NP56N8E16"9(!=-X7OQS7DG@*"^\*_";X ?$$Z;=ZGH_AFUNX=6MK2%I
M+BW@N4,?VI8P"S>65&X*"=KL0#BO8K_]J'P5>+9VG@Z[7Q[X@OI$CMM'T-M\
MO) +S,1M@11DLTA&,8Y/% &GXA^)GB*Z\;:AX7\%^'K'6KS2K6"[U&[U34C9
MP1B;?Y4<>V.1G=A&QS@*!CDDXKN_#E_?:IH=G=:GIC:/J$B9GL'F68POT*[U
MX8>A'4>E>._&2]^&*^+4?Q!XLN/A_P"-+2R7R-9L[E[*9X"2P0.R^5<H&S^[
M8/@]AGGN_@EX@UOQ3\+M"U3Q$K?VI.DNZ9[8VS7$2RNL,YB/^K,L2QR%/X2^
M,#% ';A%!S@9]<4AB4G)Y-%% "3V\=S$T4J++&PPR. P/U!IT<:Q(J(H1%&
MJC  HHH  @!) Y/6@(%! XS110 *@4\<5&;2$W G,2>>!M$NT;@/3/6BB@"1
MD#')YHV\#KQ110!%%9P0&0Q0QQ&0Y<H@&X^_K7D7CQ0O[37PF Z#2M<_]!M:
M** /7H+."V+F&)(BYR_EJ%W'U..M2LH=2K %2,$'O110!';VT5I&(X(DAC'.
MR-0H_(47%K%=QF.:-)8SU210P/X&BB@!ZQJF-H P,# Z#TH$:KNP.&ZBBB@
M"!5P.![5%%900-(T4,<32'+E%"EC[XZT44 /EMXY]OF1K)M.1N4'!]>:>!@4
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>plx-20221109.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2022 9:30:38 PM-->
<!--Modified on: 11/13/2022 9:30:38 PM-->
<xsd:schema targetNamespace="http://protalix.com/20221109" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:plx="http://protalix.com/20221109" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20221109_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20221109_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>plx-20221109_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2022 9:30:38 PM-->
<!--Modified on: 11/13/2022 9:30:38 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20221109.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="plx_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>plx-20221109_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2022 9:30:38 PM-->
<!--Modified on: 11/13/2022 9:30:38 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="plx-20221109.xsd#DocumentDocumentAndEntityInformation" roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="plx-20221109.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638039718385332008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638039718385332008" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638039718385332008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638039718385332008" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638039718385332008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638039718385332008" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638039718385332008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638039718385332008" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638039718385332008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638039718385332008" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638039718385332008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638039718385332008" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638039718385332008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638039718385332008" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638039718385332008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_638039718385332008" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638039718385332008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_638039718385332008" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638039718385332008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638039718385332008" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638039718385332008" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638039718385332008" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638039718385342007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638039718385342007" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638039718385342007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638039718385342007" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638039718385342007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638039718385342007" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638039718385342007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638039718385342007" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638039718385342007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638039718385342007" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638039718385342007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638039718385342007" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638039718385342007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638039718385342007" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638039718385342007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638039718385342007" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638039718385342007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638039718385342007" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638039718385342007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638039718385342007" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638039718385342007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638039718385342007" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638039718385352026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638039718385352026" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139622966256816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  09,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>plx-20221109x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20221109.xsd" xlink:type="simple"/>
    <context id="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-11-09</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Tc_T7mz-mJC3kOA4LC7sa89mg_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Tc_sVUa17hMq0W33_jgPd3y5w_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Narr_QS8DILQKSk-3YvWrdMdGHA">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Narr_nAleQOddbE-f-k4qBCE5zA">2022-11-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Narr_xWEMR8EXtkSkzahOuJHSlA">Protalix BioTherapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Tc_QXIDQcOE2UezTFAT11XFxQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Tc_eZA7gIe0KUOloKqa95GvwQ_1_2">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Tc_LvImTlvUi0y95kNnu0jVaQ_1_4">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Tc_Dl4hfLEUy0qcDk-GpQIdKw_4_0">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Tc_9eJfTcXG5USFrM5aGX44Wg_5_0">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Narr_v76KKfgy_06MsMf6PXjmsg">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Narr_O1B3d_Mly063zKsTR3G8vQ">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Tc_4BCiZXZ-eUGThdqmUYBkJQ_6_4">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Narr_-ju0D57mLEyp1hgWnHOeSA">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Narr_GgrIjYgJKUuBx-FdNXuhOg">696-9345</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Narr_lchaQwHWk0CStm6eLRZ_tg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Narr_QN8_TqgYAEKiZPuLHLMNeA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Narr_tvjnCsTJ_0KHZOAcMj336A">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Narr_UCN9vhWtIEOzzlABS30FDA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Tc_PBSWgn6wgk6c6f7kVAKYfg_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Tc_U56AqH8BG0qxXjtTQNy94A_2_1">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Tc_zqJe2aFa90C_qZQzl8QZfg_2_2">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ"
      id="Narr_zo1V11_yfkmqSeIktAMmXA">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MX!>CJQ8('[?X_])-I0;C('_P].BT;5#T>EW/Q]BJ=</'[3Z/U @V>L=1<($
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M/UY_ 5!+ 0(4 Q0    ( &DX;E4'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ :3AN53Q7ON#M
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ :3AN59E<G",0!@  G"<  !,              ( !RP$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " !I.&Y5SKD"H&P$  !8$0  &
M            @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ :3AN59^@&_"Q @  X@P   T              ( !K@P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !I.&Y5EXJ[',     3 @  "P
M    @ &*#P  7W)E;',O+G)E;'-02P$"% ,4    " !I.&Y5'#AEZC\!   \
M @  #P              @ %S$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ :3AN520>FZ*M    ^ $  !H              ( !WQ$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ :3AN5660>9(9 0  SP,
M !,              ( !Q!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  #A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plx-20221109x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plx-20221109x8k.htm">plx-20221109x8k.htm</File>
    <File>plx-20221109.xsd</File>
    <File>plx-20221109_lab.xml</File>
    <File>plx-20221109_pre.xml</File>
    <File>plx-20221109xex99d1.htm</File>
    <File>plx-20221109xex99d2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20221109x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "plx-20221109x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20221109_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20221109_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20221109.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20221109",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20221109x8k.htm",
      "contextRef": "Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20221109x8k.htm",
      "contextRef": "Duration_11_9_2022_To_11_9_2022_LYOLLfduyUioFUM3Yxx2KQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "plx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://protalix.com/20221109",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001558370-22-017549-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-017549-xbrl.zip
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M]F;D+C\2_TZ>G<IZW_\'4$L#!!0    ( &DX;E58#N +DP0  )XJ   4
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M'\<A_>&T4D2:I7I=8KI(M0EVB88&NMO.H)K5ZV$371/;U@T#G=JZUB+!*Z+
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M>F\B"T YS>D_'WYRY.ZBUM8>NW<_3CN7M_7$TO4Q(9D0Q$^W-!;PDN9J]VS
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M79+-)%N]6J?7$(D-4?G&XG\W.V>9@JZ!VO#4\)4)?;6B;621_(PXJJWWQG'
MW\[D>0^-^6T9;+VR1*8-FU&+A61NN_QI..8#2'^=AR&\AYH<X[!.NB+/ ;#8
MX*QGB(_?$\M>?S]ZEGNTM#F_V-$>:MLT5Z!G##DZ3Q)%(3TDPW1:$_FVVUVT
M2K]BA]C>T@!^HWYS<(M^Z)+.&RK!O$%CKO[LN2?:SV/;!$Z/BQ^,!8A_ZWR6
M=Q]$TFX0?89!)&W?(/J0(T84E-V V?B R=&I%"KC%D$%ZK_2J%*?H#/L8O\S
M&?M4OS2Z/D)#5VR!AQ:E>17HX;12'*]$''P<55OS85$[M7R__JPAO/X;2T\3
M9&]9-B\E8!:9[TK3'-;MLJ\^<O;5\O.YGE6Q6KBXR=;N*OGJ1C2_',F0]1>6
M'CW=#L+PJ^8,T$*5R<Q?S3-&2,6>PQ:L="<XKRE(8/#7;>CB!UT]:Y V-IIT
MC8-6Q%;N@P)T]<.C&0"L.NRY;<N&3FG\%BX(O-DJ=3S!Q^?NQ]WFE=Q5=O_P
M\H=<I%ZA:PE>>L_EF;5*3>:3[_G1[W^66["BW[UTV*W!JX-9!<G,G;-&7%)
M,VK4O^[)>TL[HLC\QN</BU:)RY52+5LL/*#30JGV+5_)EO-WM4*N>NCWMW"3
MXS=[]L@6[@AXVX\)O*]2OV(58IE9V XJER'\=E"Y%*RW;$5GIZ+SJ#P=968;
M 6D%(R#P@K3*-NN-]BCFQ-"9;=GH%#MM_,HEX)W"?&Q,H_O3,UL/:3LUW28J
MWT%-V:DFVZ^G=!%,I]]E9DF3-'.XB?+C;UB4V#<L['<ZS&%[ KZO];??*'P:
MC3 %D<N)&-/D/3JYE8694=>^I6NS@Z[/T]^&I8W@5]OM&B?_#U!+ P04
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M*[1O.8[]P)M3;X ;%_%M$\\-"Q-K;COW[7\,[#D/V"6_8S?>W'+_8<@K\.^
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MP!N&]\P.Q=\7O@UZW+_'Q9UQQ^G^^!!$JSLK]@JEVRWWQ805)X+\$O@W&U6
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M#I>_G4X@N,.J7%$>96T42(FRE5V50L9:M12LCOLNZZ,]8_ECAK,UU)F=#:O
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M1 FVEW9=+Q(3\Z4P#F;RG=)?7K;^1@,0)/-*&#0 /?Y]YCG GF##QG&)6+V
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MU-3!HB@W3*^]\B 3[?@<$C-+1J-<REK]$[X(7\]5XCHL-7M\59I&JUD[K@"
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M+WL//;>:=+*GA6&@&:<1P#("6-G,]'M'A#!"&"%L!6&5S2\6T4$W 8P EA7
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M-C9%U1W+J<X7QS^>RER/K/ZQ\^//*I^I2B<2OSMPL>N4U>,?A_RXTW^HX\$
M@^:Z4-U,,5F#WN!H6*F;JHM1)J"+K@X]&<=A[:.MTU[IJ7+BO9J+2S.5!:;D
M*S3UQJS[&(C_.O>SCDR>8N2SFTR/="6.CGK[S_=&X'+YS19)K^]FG3/ML,I<
M5XOC3*>I*C#=#P\/]_M/AL_WZ&F_[@T)2W(E+8:HLN&ZL-TF1;R\?SX@(21I
MEZ-<Q=%&QJ;*=A.3Y[)TZCC^TB;_&<@/+*,9$]R!=0A"B$T:/&,QK&P<-/+7
ML[!*X_69LK1#>> WQ#D,\A34M_@>5(1^%T][!_C9_+:F&*V9#$8?YV8>N1G_
MWIU;61Z/8):NNW.L]J/*UMR7(V?RNE)#TKNOI';[ARU&\+(/_9];A=&/@IN?
M)4SA9Y7^O3??\][L59:4:@>;]!5LZ>^UJ_1XL69-]70BG$VPC_E-EW#!8- _
MNE$W1T?I?K\_Z/U>3A[ 6L$UOX%@9#IY$"E-M2MSN3C6!<\ZRDUR'8W2DZ/E
M_N\?]O:?!M]<[DK(OY$ONIM[^VWN7;X2;\W$?!+[#@Y[/SV]FX,LBGOL.**(
M[HH'M[O?6Y2Q"U=8F>GQX:>KVJYHC] N4,1^O[6G";RFLO>.H@ZVHZ@+:RK,
M>R->:G.5*>B3JK$F)V21BM-,*Z?%F]R,9"XNI57BE79*.LQZ4A2F1C0@+I6K
M1U/M' RN,&,:*#<3&N*MQEJ<$B=EF8--9)%%9<2OO0^]'QX.GO6'KXU)>:)7
MMIZ(DW2J"^TJZY\<&RLNU*0N]$3F3J>21LK'DF]4F0+61PS!$0AF?2U'=A&I
MVSD<',GD>F*Q_O3XX9C_6;?YM*MBUQ#X].3RW?G9VXXX=U:JG)=];U#TP0O>
MFJ@1.UO$RU\^7/WR_KYI[XCW@ _3D;)>U 8''<$AYM[%)<9Q<VW5WFW"#X86
M24\\>O^O#V?B9(HI$ED<7[S][;%X='7RX8Q_[0@I1MJ4"!.G,N$7H22)F2+^
M74!(D]IQ@,NRFJJ9RDU)TMH1I35IG;"0$X?Q"J9(-"CYPXL^Y-DJ7![I0H(C
MU9(T>K=2NG!A$,PP6@A=\=]+JQ&X0@VPKE.5YV<W<?-<O5T3/H.OY#VW.$:R
MG(.?#F X,<?]2A]<$647L! QDL3+L':A;DJKO+UQ"U>I:>=CUHKWJG908^<$
M+ J;#-J7^ YTN13*D>_2+L-<L%.IR@$MK="P=#.&F6$G\ I/R-@25#@V2:4R
M)2(F.1ZKI/+[8HF&M*&A,JE<X$UO.%,FP*Y8SV)-:H^"T():V6CB/?+X;EO]
MZ.7;D\?$"2*4K/8.*/#KW,' =_J61Z]?867L82Y_ZP[Z^^)1N>9J)%S-X\;7
M5&U?(],ZKT2)H7#!^;R7]S]AKWN[V*MU7T@$"@U)%&5M$?&H<9WGBVX*>9X4
M*NV(W !D2-B98M(V)QUQ<?9FD5/ZK2,2:YSKPK]=0QY_>'AT\'38Q11XR_AI
MNB>0_QDT S/[M%HT7P(V,<4SE>I]#=1TAW]M,SF!0-OCA_L']._P"UD.GR"@
M ZM*JHLDK\'E7>RQ9/]A509=)'OC% M< FZP=R%YQDCU&!M46VSL-AKNE04"
M&RQ[@CA!OXFY@DDC(G4.B1E;,\6T=4HFL<ID1<)BL,$@TUBRE[(0@X/^JGJL
MJ0XL+VS,F-:[4-(Z6O'8Y C\Z99G-\FPA".H,JO4+CA/2\H5V>VX'.T]=S00
M%QDH]];J_/Q\N270AHF5TQ:=]-;+D[<G[T_/>+!%QU^Z/'_U)ESAC0P7W_Q\
M%1^3X BY.^GX9MF:<J\]9V4!%HA-@;BMAOE^Q8 $8 =L7U\BR=CN%].H,(OT
MJC3O8)'>S[/%!7:I2+<)NK @N#I)E&KD9IT?_-!7VMX-2P=78Y:\<G*LJL4V
MEA'A\#6&%E&NJLGJ<DFM6E(KSL>[7YDLH:$S\G4[GRN&$[M?U Z$=$[ENI$2
M +T33:E_V&2@!D5F60J,"@Q@"K+="\9!O/,!/M<E-IC$QS-;YE\%$6S+H]R>
M%]K)3K?C#D KG6BX-N4](6D%8*9@QD;WPJ&:53.-R4((LJ)RY!#A>!R&GF+2
MS(584.FR^BI,_;S,QKT& H?[^_WAU49,Y+GDC1/%?0P<I""4J\<4F%<MZ61(
MW]Z<N8)0YQKA-U@O8)S$5,D"8@.T+$I#)2KRI1S 151"[_%".-!KQ7-K('\5
MU# 4I]69&K%>KL>J2V@%\D#3=7PP.%$%[0J]Q"4U#PT03N@I"4Z"8%+];ZT0
M'O+.SS.=9'BSF"BO<*K$BZF_64KM$PAZBE\M!<B8O:00-0<AA6LR;JI(N\9.
M@,7&4N>U51V\3*%\G4N;+R*/KW5:J 6(']65-_[A1@985C68)0$$')&:.WX_
MQN"\@8,A_(2FH L,?2D=\%^GV1!Z8O#3T.$"%"8E*Q+U9RS.;E12<Y#]RQC;
MJFQ/1)$P$T6!MT>+7MLZM+'20]&IKBH?L5/-41<U.U,CYL9>^W>B*E9F+FTJ
M3&W%Q'@$)1.,-_,AT@3+J0RV-)JQ@+>OZ7;$@7(&%LI@(%>!+%37K<3\$4/^
M6FBB\$.%/7:]P*CO*&BZAS#IK+:F5-SYD<(,%I0AAK G"_'H[!UB;7 FJ:T%
MLR!OW@!&S ,BKQ5'J;*N,F-C%DRV4A&M4-TG>S0ER67BTR_-)F,JEHJ 1KZG
MP/1^S.,[RBV&3-,\,[S87+/\;J8A,#7YGDQ"J=2-=LSCNI@BJ"R .5T[M@(*
M=8YS/4VF(^K[J(:E"DG)"6N\+L8U&6?7V6)CL=,P2,96G+I<IM%DR]P66'DK
MI5+2-JX:D#=:0K5-H^[4;$,DW)'DN\5@1.O#)H,"TFM>U3*K86Q(YS$@]X81
M?IS5&BQF]DUE2GZ)K 5++1;9@D0&KHHL HW"C[NZ) XH;VM^ARQ6P5+Q@L&5
M$47OS5C;^!$3;WY+@Z7A42B!N?A.S,C.R@(G(P,O]'7+.CMJZ@'P@['JNE(F
M5"[N]GL#7SK=!!"%^"UFXW0!$6:_$1]@6$G@*(=H,AQ(%5PERP69PAG$(KKL
M?.&, W5YR.KM(&+HWON8MS+JS5I*4A5_( H)O" M@J/E1 R5!2A@29)Z2MX\
M($@Y*HPE9J2*>T.<SZB/9551"#YR%34VBD3F%-3>UF^1-:U+2Y3<#7%%G_\9
MMMJN5F\$,=M?$[O^6GF:^_;"I58W8+C2;@9<;_8KY41U?8^,'(.+QS*?RX4+
M]?K#P][^P3^&H8_+7^MOM _NHBGQ,QO1_LQ>^E;QG<!;&4K:&;?( 6TQ/MS)
MHS>C97WNB^WHT>T$K)7M,!EH>D(5N_NLN=ZZ^L>DG:.<ZC%PN4[E8@X]HQ0G
M-&B2D9F7%+HX4S01 G75K@=8!DIM.2_+3I=?H#_$0;\#%2-_^8Q_ZZWZ3!=-
M*::)!C-I#&4H>FRW,)T0@9&+9@/"X-65@#[L\&-YB/4N-7,V-G^1;?5%@<:R
M @I9F*"_$ ,(/EO?#.,#$ Q#$+!#[@>&%D_GB\Y?AAN-SZ52=VDU+"YFB"&P
MUW\?N;4NM V"%ZA;<R%_%3X&B$+(Y?X3/QPB#1!DW7O^YSM)^>XX'@DYB.^L
MP>P>0?U'^B%\C++6$=!IM^I )BH(6C<TZ5#AA9N<,C4EK8*T34VJQYHKK9+:
M,/]09 =L.]O;[GZZTT'WQ'GE,Z^%F:F\U=NPC!% 7*)\W,WM.Y22NKQZ+,!<
M@(=69];V;H^UI.]%:$*".>A2(.Y"&G(F<Y_<&M&NB9F6S9I;71:<@7'TTV4&
M.@5RP0\-$2&KN1+/2-S(%=BI0IF\T+"&(O2;&0S%F60HLIPJV!+8S_-B62,.
M];9.D[BDW/=(42)GA,V?^8PI9RM J;9)3'YFV.DNI:\Y1J),Z T;9"SML"\
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MNHQUB)%Y@5PO6SL033P:J;#PH,T>R4!]<^QQ03EVC$/0S348:744:AY,^$R
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M32_^#U!+ 0(4 Q0    ( &DX;E5MWYFBO@,  -8,   0              "
M 0    !P;'@M,C R,C$Q,#DN>'-D4$L! A0#%     @ :3AN5;*N4;*<!0
M/3\  !0              ( ![ ,  '!L>"TR,#(R,3$P.5]L86(N>&UL4$L!
M A0#%     @ :3AN55@.X N3!   GBH  !0              ( !N@D  '!L
M>"TR,#(R,3$P.5]P<F4N>&UL4$L! A0#%     @ :3AN54]#_FN,%@  %ZD
M !,              ( !?PX  '!L>"TR,#(R,3$P.7@X:RYH=&U02P$"% ,4
M    " !I.&Y5SIXD*^(K  #8 @, %P              @ $\)0  <&QX+3(P
M,C(Q,3 Y>&5X.3ED,2YH=&U02P$"% ,4    " !I.&Y5(/ TU[89  "-:@
M%P              @ %340  <&QX+3(P,C(Q,3 Y>&5X.3ED,BYH=&U02P4&
2      8 !@"- 0  /FL

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
